Cargando…

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes

Targeting immune inhibitory receptors has brought excitement, innovation and hope to cancer patients. Our recent work revealed the immunological effects of blocking the CTLA4 and PD-1 immune checkpoints on T cell receptor usage among peripheral blood cells, and further uncovers how the expansion of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robert, Lidia, Harview, Christina, Emerson, Ryan, Wang, Xiaoyan, Mok, Stephen, Homet, Blanca, Comin-Anduix, Begonya, Koya, Richard C, Robins, Harlan, Tumeh, Paul C, Ribas, Antoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108466/ https://www.ncbi.nlm.nih.gov/pubmed/25083336 http://dx.doi.org/10.4161/onci.29244

Ejemplares similares

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
por: von Euw, Erika, et al.
Publicado: (2009)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade
por: Pilones, Karsten, et al.
Publicado: (2014)

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
por: Comin-Anduix, Begoña, et al.
Publicado: (2010)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts
por: Linch, Stefanie N, et al.
Publicado: (2014)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014)

PD-1 blockade induces responses by inhibiting adaptive immune resistance
por: Tumeh, Paul C., et al.
Publicado: (2014)

A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication
por: Zhou, Jing, et al.
Publicado: (2018)

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products
por: Nowicki, Theodore S., et al.
Publicado: (2018)

Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity
por: Schendel, Dolores J., et al.
Publicado: (2013)

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure
por: Shin, Daniel, et al.
Publicado: (2015)

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
por: Garcia-Diaz, Angel, et al.
Publicado: (2017)

Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade
por: Frankiw, Luke, et al.
Publicado: (2023)

Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment
por: Demaria, Sandra, et al.
Publicado: (2013)

Radiotherapy induces responses of lung cancer to CTLA-4 blockade
por: Formenti, Silvia C., et al.
Publicado: (2018)

Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
por: Rudqvist, Nils-Petter, et al.
Publicado: (2023)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade
por: Abril-Rodriguez, Gabriel, et al.
Publicado: (2022)

A novel system for cloning human TCRs: Cutting short the way to TCR-based anticancer therapy
por: Kobayashi, Eiji, et al.
Publicado: (2014)

Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies
por: Omokoko, Tana, et al.
Publicado: (2015)

Polyamine blockade promotes antitumor immunity
por: Hayes, Candace S, et al.
Publicado: (2014)

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
por: Niehr, Franziska, et al.
Publicado: (2011)

Interferon blockade in lupus: effects on antiviral immunity
por: Steiger, Stefanie, et al.
Publicado: (2022)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity
por: Cartellieri, Marc, et al.
Publicado: (2013)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

The S100A8/A9 complex reduces CTLA4 expression by immature myeloid cells: Implications for pancreatic cancer-driven immunosuppression
por: Basso, Daniela, et al.
Publicado: (2013)

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
por: Ascierto, Paolo A, et al.
Publicado: (2011)

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

A(2A) blockade enhances anti-metastatic immune responses
por: Beavis, Paul A, et al.
Publicado: (2013)

Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma
por: Zhang, Mengxian, et al.
Publicado: (2012)

Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade
por: Liu, Jiao, et al.
Publicado: (2022)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

Protective Immunity to Nematode Infection Is Induced by CTLA-4 Blockade
por: McCoy, Kathy, et al.
Publicado: (1997)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uh75kfrvep7e240cu54fmcf407